Table 1.
Characteristics of erenumab responder patients and control group at the time of erenumab treatment initiation
| Variable | Erenumab responder patients (N = 82) | Migraine controls (N = 82) |
|---|---|---|
| Female (n, %) | 70 (85%) | 70 (85%) |
| Follow-up time, months (mean) | 12 | 12 |
| Age, years (mean, SD) | 45 (10) | 45 (10) |
| Age distribution, years, % | ||
| < 30 | 6% | 6% |
| 30–40 | 23% | 23% |
| 40–50 | 40% | 40% |
| 50–60 | 22% | 22% |
| 60–70 | 9% | 9% |
| Medications (prescriptions in 12 months pre-index) | ||
| Triptans, % | ||
| Selective serotonin 5HT1 agonists (triptans), N02CC | 68% | 39% |
| Other pain medication, % | ||
| Propionic acid derivatives, M01AE | 43% | 35% |
| Paracetamol, N02BE | 21% | 12% |
| Opioids in combination with non-opioid analgesics, N02AJ | 18% | 5% |
| Coxibs, M01AH | 16% | 10% |
| Acetic acid derivatives, M01AB | 15% | 9% |
| Combined, other pain medication | 68% | 33% |
| Antiemetics, % | ||
| Propulsives (metoclopramide), A03FA | 13% | 1% |
| Prophylactic medication, % | ||
| Non-selective monoamine reuptake inhibitors, N06AA | 31% | 9% |
| Angiotensin II receptor blockers, C09CA | 31% | 10% |
| Other antidepressants (incl. venlafaxine, mirtazapine), N06AX | 21% | 5% |
| Other antiepileptics (including topiramate), N03AX | 20% | 7% |
| Selective beta blockers, C07AB | 15% | 11% |
| Muscle relaxants (botulinum toxin), M03AX | 11% | 0% |
| Combined, prophylactic medication | 66% | 23% |
| Other medication, % | ||
| Proton pump inhibitors, A02BC | 28% | 21% |
| Corticosteroids, R01AD | 17% | 11% |
| Sympathomimetics, R01BA | 16% | 13% |
| Other centrally acting agents (incl. tizanidine), M03BX | 16% | 11% |
| Selective serotonin reuptake inhibitors, N06AB | 13% | 6% |
| Natural and semisynthetic estrogens, G03CA | 12% | 0% |
| Benzodiazepine derivates, N05BA | 11% | 7% |
| Comorbid conditions (visits with specific ICD code in 12 months pre-index), % | ||
| Acute upper respiratory infections of multiple and unspecified sites, J06 | 35% | 43% |
| Dorsalgia, M54 | 15% | 11% |
| Other headache syndromes, G44 | 13% | 7% |
| Malaise and fatigue, R53 | 11% | 4% |
| Depressive episode, F32 | 11% | 4% |
| Sleep disorders not due to a substance or known physiological condition, F51 | 10% | 1% |
| Other and unspecified dorsopathies, not elsewhere classified, M53 | 9% | 10% |
| Acute bronchitis, J20 | 7% | 2% |
| Infectious gastroenteritis and colitis, unspecified, A09 | 7% | 5% |
| Excessive, frequent and irregular menstruation, N92 | 7% | 2% |
| Other joint disorder, not elsewhere classified, M25 | 7% | 4% |
| Abdominal and pelvic pain, R10 | 7% | 11% |
ICD International Classification of Diseases, Tenth Revision, Clinical Modification, SD Standard deviation
Codes following name of medication are the Anatomical Therapeutic Chemical Classification (ATC) codes